Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide

By M. Hegi, A. Diserens, Sophie Godard, P. Dietrich, L. Regli, Sandrine Ostermann, Philippe Otten, G. van Melle, N. de Tribolet, R. Stupp. Clinical Cancer Research, 2004

816 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Pharmaceutical Science

View Paper: https://www.semanticscholar.org/paper/f1c9bf315aeee735b4465740aee15c7424c15f69

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Michael Weller
2. Guido Reifenberger
3. Jill S. Barnholtz-Sloan
4. Mauro Delorenzi
5. Q. Ostrom

In Molecular Biology

1. Mauro Delorenzi
2. Ulrike von Luxburg

Citations in the corpus

• Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. (2008, methodology): “In glioblastoma, introduction of combined chemoradiotherapy of concomitant and adjuvant temozolomide (TMZ) and radiotherapy (TMZ/ RT3TMZ) has allowed significant prolongation of survival,(1,2) in particular in patients with an epigenetically silenced O-6-methylguanine-DNA methyltransferase (MGMT) DN”
• Glioblastoma: pathology, molecular mechanisms and markers (2015, background): “A number of clinical trials and cohort studies have shown that promoter methylation of the MGMT gene is associated with prolonged progression-free and overall survival in patients who were treated with alkylating agents [41, 60, 61, 65, 172].”
• MGMT promoter methylation in malignant gliomas: ready for personalized medicine? (2010, methodology): “To date, MSP is the only test that has repeatedly been shown to be of predictive or prognostic value in clinical trials (Tables 2 and 3).(11,38) At present, qMSP(31) is being used for patient selection in the CENTRIC trial (http://clinicaltrials.”
• High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, neutral): “of alkylating agent chemotherapy [II, B] [15, 16].”
• Epidemiologic and Molecular Prognostic Review of Glioblastoma (2014, background): “MGMT promoter methylation has prognostic and predictive significance in patients with GBM with better overall survival (OS) irrespective of treatment choices (84, 92, 93).”